PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

November 10, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

PIPE-307

"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
lead

Contineum Therapeutics

INDUSTRY

NCT04941781 - PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers | Biotech Hunter | Biotech Hunter